Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2. Since then, it has been very quiet about this compound. Some have suggested that Novartis has stopped development [1], an impression supported by the fact that the drug is Continue reading Following The Publication Trail of Two RSV Drugs
Why are there so few boron-containing drugs on the market? The cancer drug bortezumib (Velcade®) may be the only better-known drug on the market with a boron atom in its structure.[1] Among antibiotics, there is Kerydin™ (tavaborole), an approved topical solution for the treatment of onychomycosis caused by Trichophyton but Continue reading Not So Boring: Boron-Containing Antibiotics Create a Stir
Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1] This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into Continue reading Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study